Republic of Korea–based drug maker Celltrion announced this week that it is launching its first clinical trial of CT-P39, a proposed biosimilar omalizumab referencing Xolair. The company says that it plans to enter phase 3 trials in the first half of 2020 and has plans to commercialize the biosimilar by 2022.
Republic of Korea—based drug maker Celltrion announced this week that it is launching its first clinical trial of CT-P39, a proposed biosimilar omalizumab referencing Xolair. The company says that it plans to enter phase 3 trials in the first half of 2020 and has plans to commercialize the biosimilar by 2022.
Omalizumab, developed by Novartis in partnership with Genentech, is a monoclonal antibody approved by the FDA to treat asthma and chronic idiopathic urticaria. The compound patent for the biologic, according to Securities and Exchange Commission filings, expired in 2018. However, Novartis, according to its annual report in 2018, holds additional patents on syringe formulations that will not expire in the US or EU markets until 2021 and 2024.
Celltrion says that it began development of its biosimilar in December 2018 and added that it hopes to be the first developer to launch a biosimilar of the molecule. In particular, Celltrion says that it is focused on the US market, which accounts for approximately 70% of the branded drug’s global sales.
The phase 1 trial will enroll an estimated 171 healthy adult volunteers for a randomized, double-blind, 3-arm, parallel-group, single-dose study to compare the pharmacokinetics and safety of EU-licensed Xolair, US-licensed Xolair, and the proposed biosimilar. The trial is expected to be completed in August 2020.
In addition to Celltrion, several other biosimilar developers are targeting omalizumab; Glenmark announced its phase 1 study of proposed biosimilar GBR 310 in 2018, and Sorrento Therapeutics has completed a phase 2 and phase 3 study of its STI-004. Additionally, Biosana this year received permission from Australian regulators to initiate a phase 1 trial of its BP001.
Meanwhile, Novartis has been developing another product that could help it retain a hold on the market for utricaria. In 2018, the drug maker announced that its ligelizumab would advance to phase 3 trials for the treatment of chronic spontaneous urticaria after it demonstrated a clear dose-response relationship and improvements over omalizumab.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.